Literature DB >> 18657542

Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production.

Marc Dauer1, Veronique Lam, Hannah Arnold, Jana Junkmann, Rosemarie Kiefl, Christian Bauer, Max Schnurr, Stefan Endres, Andreas Eigler.   

Abstract

Phenotypical maturation, IL-12p70 production and migration upon chemokine receptor CCR7 ligation are currently proposed as requirements for the use of human monocyte-derived dendritic cells (DC) in antitumoral vaccination. We have previously described a short-term protocol for DC generation from monocytes including stimulation with TNF-alpha, IL-1beta and PGE(2) (FastDC). These "conventional" FastDC are mature, migrate in response to CCR7 ligation and effectively stimulate autologeous T cells in vitro, but are deficient in IL-12p70 production. Here, conventional FastDC were compared to FastDC activated with different TLR ligands. High levels of IL-12p70 were induced by combined activation of FastDC with TLR4 and TLR7/8 ligands. IL-12 secretion could be maximized by additional T cell-derived stimulation. However, TLR-stimulated FastDC failed to migrate upon CCR7 ligation, independent of additional activation with CD40 ligand and IFN-gamma. The presence of PGE(2) during TLR ligation fully restored migratory capacity of FastDC, but left IL-12p70 production and activation of tumor antigen-specific cytotoxic T cells unaffected, challenging previous findings obtained with standard 7-day monocyte-derived DC. The FastDC model thus not only represents an effective tool for antitumoral vaccination, but may also provide novel insights into human DC biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657542     DOI: 10.1016/j.jim.2008.07.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.

Authors:  Mei Zhu; Wei Xu; Hong Su; Qiong Huang; Baolong Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Transfus Med Hemother       Date:  2020-10-28       Impact factor: 3.747

3.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

Authors:  Sébastien Anguille; Evelien L J M Smits; Nathalie Cools; Herman Goossens; Zwi N Berneman; Vigor F I Van Tendeloo
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

4.  Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Authors:  Cheryl Lai-Lai Chiang; Andrea R Hagemann; Rachel Leskowitz; Rosemarie Mick; Thomas Garrabrant; Brian J Czerniecki; Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

5.  Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.

Authors:  Barbara Beck; Daniela Dörfel; Felix S Lichtenegger; Christiane Geiger; Lysann Lindner; Martina Merk; Dolores J Schendel; Marion Subklewe
Journal:  J Transl Med       Date:  2011-09-13       Impact factor: 5.531

6.  Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Authors:  Cheryl L-L Chiang; Dawn A Maier; Lana E Kandalaft; Andrea L Brennan; Evripidis Lanitis; Qunrui Ye; Bruce L Levine; Brian J Czerniecki; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2011-11-14       Impact factor: 5.531

7.  The Ability of Precursory Monocytes (MO) to Differentiate Varies Among Individuals But Is Stable Over Time.

Authors:  Krzysztof Laudanski; Mateusz Zawadka; Natalia Lapko
Journal:  Med Sci Monit       Date:  2016-07-14

8.  Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.

Authors:  Tanja Lövgren; Dhifaf Sarhan; Iva Truxová; Bhavesh Choudhary; Roeltje Maas; Jeroen Melief; Maria Nyström; Ulrika Edbäck; Renee Vermeij; Gina Scurti; Michael Nishimura; Giuseppe Masucci; Alex Karlsson-Parra; Andreas Lundqvist; Lars Adamson; Rolf Kiessling
Journal:  Cancer Immunol Immunother       Date:  2017-06-10       Impact factor: 6.968

Review 9.  Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.

Authors:  Simone P Sittig; I Jolanda M de Vries; Gerty Schreibelt
Journal:  Biomedicines       Date:  2015-12-02

10.  An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.

Authors:  Sara Nava; Marta Dossena; Simona Pogliani; Serena Pellegatta; Carlo Antozzi; Fulvio Baggi; Cinzia Gellera; Bianca Pollo; Eugenio A Parati; Gaetano Finocchiaro; Simona Frigerio
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.